Cardiovascular Business

Cardiovascular Business serves as a source for news, business insights, and technological advancements in the field of cardiovascular medicine. We concentrate on the economic aspects and business strategies that support leading clinical practices, interventional methods, surgical innovations, and information technologies. Additionally, we cover pharmaceuticals and related products that play a crucial role in establishing a successful integrated cardiovascular practice.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#313218

United States

#78645

Health/Health

#1692

Traffic sources

Monthly visitors

Articles

It may not be easy, but it changes lives: Reframing myths of healthcare leadership

1 day ago | cardiovascularbusiness.com

Leadership is not easy, but it is worth doing. According to one seasoned healthcare executive, the world needs more physicians to move into leadership positions.
CCTA shows colchicine's impact on atherosclerosis progression

1 week ago | cardiovascularbusiness.com | Dave Fornell

The anti-inflammatory medication colchicine can help reduce coronary soft plaques as seen on on coronary computed tomography angiography (CCTA), according to the late-breaking EKSTROM trial first presented at ACC.25. “We did serial CT angiography baseline and one-year follow-up after randomizing patients to 0.5 mg of colchicine daily or placebo.
AI-enabled CCTA evaluations reduce use of invasive imaging exams

1 week ago | cardiovascularbusiness.com | Michael Walter

Evaluating the cardiac CT results of patients with chest pain using artificial intelligence (AI) is safe, effective and can significantly reduce the need for downstream imaging exams, according to new data published in Nature Medicine.[1]Researchers reviewed two-year data from FISH&CHIPS, a clinical trial conducted by the National Health Service (NHS) at 27 hospitals in England.
Exploring AI's potential to transform cardiology

2 weeks ago | cardiovascularbusiness.com | Dave Fornell

The use of artificial intelligence (AI) in cardiology has moved from potential to reality, with more than 160 U.S. Food and Drug Administration (FDA)-cleared algorithms now shaping diagnostics, imaging and interventional cardiology.
PFA takes center stage at Heart Rhythm 2025 as medtech companies share new data

2 weeks ago | cardiovascularbusiness.com | Michael Walter

Pulsed field ablation (PFA) technologies were the center of attention at Heart Rhythm 2025, the Heart Rhythm Society’s annual meeting in San Diego. PFA is an ablation technology that involves using high-voltage electrical pulses to treat heart rhythm issues such as paroxysmal and persistent atrial fibrillation (AFib).
Medtronic and Abbott make progress on interoperable diabetes tech-is FDA clearance next?

3 weeks ago | cardiovascularbusiness.com | Michael Walter

Medtronic and Abbott, two of the world’s leading medtech companies, have made significant progress in their collaboration focused on improving care for patients with type 1 and type 2 diabetes. The companies have been working together to develop new continuous glucose monitor (CGM) technology that will use Abbott’s own FreeStyle Libre sensors and work exclusively with Medtronic’s .
Proactive CAD strategies fueled by calcium scores lead to benefits for intermediate-risk patients

3 weeks ago | cardiovascularbusiness.com | Michael Walter

Using coronary artery calcium (CAC) scores to guide treatment is associated with significant benefits for intermediate-risk patients with a family history of premature coronary artery disease (CAD), according to new data published in JAMA.[1]Up to 50% of all patients face an intermediate risk of developing CAD, researchers explained, and the optimal treatment strategy for that population remains unclear.
AI-based coronary plaque evaluations highlight elevated heart risks in women

3 weeks ago | cardiovascularbusiness.com | Dave Fornell

Artificial intelligence (AI) is transforming cardiovascular risk assessment, making the quantification and analysis of coronary plaques faster, easier, more accurate and easier to reproduce.
Cardiovascular Business announces its Forty Under 40 Class of 2025

4 weeks ago | cardiovascularbusiness.com | Michael Walter

Cardiovascular Business is thrilled to unveil the Forty Under 40 Class of 2025. We asked readers to nominate individuals who are already making a major impact on the world of cardiovascular health at a young age. We wanted to hear about your best, your brightest, your most radical thinkers; the people who are never satisfied by something being “good enough” or “how it’s always been done.” Reviewing the nominees, it was clear that our readers really delivered.
Quality of care for heart patients does not improve in first year of ACO participation

1 month ago | cardiovascularbusiness.com | Michael Walter

Outpatient cardiology practices that participate in an accountable care organization (ACO) as part of the Medicare Shared Savings Program (MSSP) do not experience immediate improvements in the quality of care they provide, according to new findings published in JAMA Cardiology.[1] “In 2012, the U.S. Centers for Medicare and Medicaid Services introduced the MSSP to lower cost and improve care quality across ambulatory practices by promoting care coordination, infrastructure investment and care...